（文章来源：第一财经） 美国总统特朗普计划于当地时间周四推出一个药房网站，让人们能够直接购买处方药。白宫新闻秘书莱 维特在社交平台上发文称，总统将于当地时间晚上7点在白宫举办一场活动，以推出这个名 为"TrumpRX"的网站。该网站旨在让顾客能够直接从制药企业购买某些药品，无需使用保险，并且能以 特朗普政府协商确定的折扣价购得这些药品。不过，莱维特并未透露该网站具体何时会正式上线。 ...

2月5日，诺和诺德美股股价收盘跌8.14%。该公司的重磅疗法司美格鲁肽糖尿病药物"诺和泰"在中国的 销售额首次出现下滑。据诺和诺德财务数据，诺和泰在包括香港和台湾的中国市场销售额在2025年下滑 了7%，降至约54亿丹麦克朗（约合8.53亿美元）。 （文章来源：第一财经） ...

Group 1 - Shanghai aims for an average annual GDP growth rate of 5% over the next five years, up from 4.9% during the "14th Five-Year Plan" period, indicating significant progress despite a seemingly small numerical difference [1][3] - The growth strategy focuses on three key areas: stronger support from new drivers, greater release of core functions from five centers, and substantial backing from major projects, particularly in emerging industries [1][4] - The three leading industries—integrated circuits, biomedicine, and artificial intelligence—are expected to maintain an annual growth rate of over 10%, contributing significantly to Shanghai's economic development [4][5] Group 2 - By 2030, if the 5% growth target is met, Shanghai's GDP is projected to exceed 7 trillion yuan, positioning it among the top three global cities, following New York and Los Angeles [3] - The "15th Five-Year Plan" outlines specific targets, including a labor productivity exceeding 520,000 yuan per person and a digital economy's core industry value-added accounting for over 20% of GDP by 2030 [4][10] - Shanghai plans to establish a modern industrial system characterized by "2+3+6+6," focusing on advanced manufacturing and the development of six emerging pillar industries and six future industries [5][10] Group 3 - The city is committed to enhancing its international competitiveness and supporting technological innovation, with a focus on maintaining a stable industrial output value that aligns with GDP growth [7][8] - Recommendations include optimizing industrial land use and ensuring that industrial planning aligns with Shanghai's development needs, particularly in the biomedicine sector [8][9] - The emphasis on research and development is evident, with R&D expenditure expected to reach 5% of GDP by 2030, and a focus on fostering a culture of innovation among scientists and entrepreneurs [11][15]

【时政新闻】 ①美国至1月31日当周初请失业金人数 23.1万人，前值20.9万人； ⑥世界黄金协会：1月全球黄金ETF吸引创纪录的187亿美元资金流入； 【市场动态】 ①美股三大股指期货盘前齐跌，截至发稿，道指期货跌0.32%，标普500指数期货跌0.51%，纳指期货跌 0.78%； ②欧洲主要股指齐跌，截至发稿，英国富时100指数跌0.51%，法国CAC40指数跌0.18%，德国DAX指数 跌0.66%，欧洲斯托克50指数跌0.81%； 【公司新闻】 ①蔚来汽车盘前涨超7%，蔚来公司发布盈利预告称2025年四季度预期实现经营利润7亿元至12亿元； ②美国1月挑战者企业裁员人数 10.8435万人，前值3.5553万人； ③欧洲央行维持三大利率不变； ④英国央行将基准利率维持在3.75%； ⑤乌总统办公室主任：本轮乌美俄三方会谈富有建设性； ④谷歌A美股盘前跌超3%，报320.72美元。 ②叮咚买菜美股盘前跌超8%，美团宣布拟7.17亿美元收购叮咚； ③Wolfspeed美股盘前跌超17%，公司第二季度调整后每股收益和销售额均不及预期； ...

当前全球经济格局深度调整，地缘政治冲突、政策变动、汇率波动等风险交织叠加，上海企业面临的外 部环境日趋复杂。顶住压力实现了外贸逆势增长的上海，今年明确"全力稳外资稳外贸"。 为了破解企业出海痛点，马炜提出，要构建系统化风险防控赋能体系，打造精准化风险预警服务平台， 优化精细化政策支持与兑现机制，健全协同化出海服务生态体系。其中，建议优化税收激励政策，提高 企业海外安全防护、技术研发等投入的税前扣除比例；设立分类分级的专项补贴资金池，对高风险地区 业务、高科技领域企业给予重点支持。 应对欧盟碳关税 近期，欧盟围绕碳边境调节机制（CBAM）连续释放出新的政策信号。2025年底，欧盟方面表示，在按 原计划于2026年进入正式征收阶段的基础上，正在推动将碳关税的适用范围，从目前主要针对钢铁、 铝、水泥等基础原材料，进一步扩大至使用钢铝较多的下游制成品，同时加强对转口、轻加工规避行为 的监管力度。 根据《上海市国民经济和社会发展第十五个五年规划纲要（草案）》，为了推动国际贸易中心提质升 级，上海将增强贸易枢纽功能，加快贸易创新发展和结构转型，优化升级货物贸易，拓展中间品贸易， 着力发展服务贸易、数字贸易、离岸贸易、绿色 ...

Group 1 - The price of computer components, particularly storage products like SSDs and memory, has significantly increased, leading to higher consumer costs for building PCs [2][4][5] - In the past three months, memory prices have surged by approximately three times, while SSD prices have doubled [2][5] - The cost of essential components now constitutes 35% to 50% of the total budget for a basic office computer, forcing consumers to compromise on CPU specifications to accommodate storage costs [4][5] Group 2 - Despite rumors of tight CPU supply and price increases, consumer-grade CPU prices have stabilized after an initial rise [3][5] - The ongoing price hikes in storage components are attributed to structural shortages driven by the large-scale application of AI [5][11] - Market research indicates that the global laptop shipment volume is expected to decline by 14.8% in the first quarter due to rising storage costs and supply chain pressures [11] Group 3 - Different consumer electronics brands exhibit varying abilities to absorb the impact of rising storage prices, with lower-end brands facing greater risks [7][11] - Apple is expected to leverage its supply chain advantages to capture market share amidst the turmoil, potentially avoiding price increases for its next iPhone model [12] - The price of NAND Flash and DRAM has risen significantly, with estimates of a 90% to 95% increase for DRAM and a 55% to 60% increase for NAND Flash in the first quarter [8][12] Group 4 - Companies are adjusting their product strategies, including reducing storage configurations to manage costs, but this may not significantly alleviate the impact of volatile storage prices [9][12] - The overall market for consumer electronics is anticipated to shrink due to the pressures from rising component costs, particularly affecting smaller manufacturers with limited supplier relationships [11][12] - Recent price increases have also affected other components like motherboards, although the extent of these increases is less pronounced compared to storage products [6][11]

2月5日，美团在港交所发布公告，宣布以约7.17亿美元（约49.8亿元人民币）的初始对价，完成对叮咚 买菜中国业务100%股权的收购。 而美团的小象超市一直以前置仓模式为主，直到2025年12月，小象超市在北京开设了首家线下店。 从竞争力看，自有品牌和价格依然是重点。庄帅表示，前置仓的差异化竞争一直存在，各家都在强化自 有品牌和单品优势，例如盒马的自有品牌和日日鲜系列，京东七鲜的自有品牌和24小时系列、美团小象 的象大厨系列等。价格方面，七鲜时常打出"击穿价"宣传产品，而阿里和美团已经开出多家线下折扣 店。 也因此，虽然叮咚买菜连续多季度盈利，压力仍然不小。上一轮生鲜零售大战中，每日优鲜出现爆雷， 叮咚在存活且胜出后，虽然实现多季度盈利，但仍属于微利状态，资本市场并不看好，公司市值长期处 于5至7亿美元低位。 对此，网经社电子商务研究中心数字生活分析师陈礼腾认为是多重因素下的抉择：前置仓模式履约成本 高、生鲜损耗难降，增长陷入瓶颈。同时生鲜即时零售赛道已成美团、盒马等巨头的竞争场，垂直平台 很难抗衡，生存空间持续被挤压。叠加资本市场估值低迷、早期投资者有退出需求，出售能实现股东与 团队价值，而且与美团的高度协 ...

Core Viewpoint - The competition among JD.com, Alibaba, and Meituan in the fresh food instant retail sector has intensified, with Meituan acquiring Dingdong Maicai's China business for approximately $717 million, aligning with its long-term strategy in grocery retail [1][2]. Group 1: Acquisition Details - Meituan announced the acquisition of 100% of Dingdong Maicai's China business for about $717 million (approximately 4.98 billion RMB) [1]. - Dingdong Maicai operates over 1,000 front warehouses in China and has over 7 million monthly purchasing users as of September 2025 [1]. - Dingdong Maicai's founder expressed a shift from competition to collaboration for future development [1]. Group 2: Strategic Value - According to Zhang Yi, CEO of iiMedia Consulting, Dingdong Maicai's mature front warehouse model and its presence in East China provide strategic value to Meituan, helping to fill gaps in its grocery retail operations [2]. - Fresh food is considered a critical entry point for Meituan in the instant retail space, especially as competitors like Alibaba and JD.com are aggressively expanding their fresh food offerings [2]. Group 3: Competitive Landscape - JD.com, Alibaba, and Meituan have different focuses within the fresh food instant retail sector, with JD.com emphasizing supermarket formats, Alibaba leveraging Hema Fresh, and Meituan focusing on front warehouses [3]. - JD.com plans to combine its physical stores with front warehouses, aiming to open multiple new stores by March 2025, with over 70 stores expected by January 2026 [3]. - Alibaba's Hema Fresh plans to open nearly 100 new stores by August 2025, expanding into over 50 new cities, with a total exceeding 500 stores [3]. Group 4: Market Challenges - Despite Dingdong Maicai's profitability over several quarters, it faces pressure due to high fulfillment costs and challenges in reducing fresh food waste, leading to a bottleneck in growth [5]. - The fresh food instant retail market has become highly competitive, making it difficult for vertical platforms to survive against giants like Meituan and Hema [5]. - Dingdong Maicai's market valuation has remained low, between $500 million and $700 million, reflecting broader market conditions and investor exit demands [5].

第一财经记者实探深圳水贝，多位水贝黄金门店工作人员告诉记者，上游料商不放料了，根本拿不到 货。还有门店负责人表示，今日已经不看大盘金价了，要拿现货每克要加几十元，亏太多卖干脆关门。 专家表示，料商选择锁仓不出，是由于部分料商未对库存进行保值，使得价格风险存在敞口。 （文章来源：第一财经） 近日，金价、银价暴涨暴跌坐起"过山车"，剧烈波动之下市场没有现货卖了。 ...

Core Insights - The core viewpoint of the news is that China's medical insurance purchasing mechanism, centered on centralized bulk procurement and drug price negotiations, is reshaping the pharmaceutical industry landscape in China [1] Group 1: Policy Changes and Trends - Since 2018, China's pharmaceutical policy has entered a new phase focused on value orientation and collaborative governance, transforming medical insurance from a passive payer to an active strategic purchaser [1] - The current policy shift emphasizes "cost-effectiveness" and "value-based healthcare," moving away from mere cost control [2] - The establishment of a national drug price negotiation mechanism supports the accessibility of innovative and high-priced drugs [2] Group 2: Drug Procurement and Pricing - The bulk procurement policy has transitioned from pilot programs to normalization, effectively reducing prices for generic and chronic disease medications [2] - The proportion of newly listed drugs entering the medical insurance directory within the same year of approval increased from 32% in 2019 to 97.6% in 2023 [2] - The number of drugs procured through national centralized procurement has reached 490, covering various treatment areas including chronic diseases and anti-tumor medications [3] Group 3: Innovation and Market Dynamics - Domestic innovative drugs account for 71% of newly added varieties, indicating a rapid shift towards high-value areas in the pharmaceutical industry [3] - The report anticipates that by 2025, the patient burden will be reduced by over 50 billion yuan, while improving the efficiency of medical insurance fund usage by 22% [3] - The introduction of fast-track approval channels for rare disease drugs has significantly shortened the time for new drugs to enter the medical insurance directory [4] Group 4: Challenges and Recommendations - The report highlights challenges such as the lack of a robust quality supervision mechanism for bulk procurement and insufficient collaboration between medical insurance and pharmaceutical innovation [8] - Recommendations include enhancing the drug value assessment system and establishing a unified drug usage tracking system to monitor the procurement and usage of selected drugs [9] - The report suggests building a multi-tiered payment system to address the accessibility issues of innovative drugs [9]